JERUSALEM, Jan 19 (Reuters) – Israel has not identified any evidence linking strokes to an updated coronavirus vaccine made by U.S. drugmaker Pfizer (PFE.N) and its German partner BioNTech SE , according to a health ministry official.
On Friday, the U.S. Food and Drug Administration (FDA) and the Centres for Disease Control and Prevention said that a safety monitoring system had flagged that the shot could possibly be linked to a type of brain stroke in older adults, according to preliminary data.
"We have not turned up such a finding, even after we went back and rechecked all our data after the FDA announcement," said Salman Zarka, the head of Israel's coronavirus task force said in a video briefing sent to Reuters on Thursday.
Some 389,648 people in Israel have so far taken the shot, which targets the original strain and its BA.4/BA.5 Omicron subvariant.
On Wednesday, the European Union's drug regulator also said it had found no safety signals in the region related to Pfizer's bivalent shot.
Pfizer and BioNTech said in a statement on Friday that they were aware of limited reports of ischemic strokes in people 65 and older following vaccination with their updated shot.
Pfizer further noted that neither the companies nor the CDC and FDA had observed similar findings across other monitoring systems and said there was no evidence to suggest an association with the use of the companies' COVID-19 vaccines.
Our Standards: The Thomson Reuters Trust Principles.
Thousands of abortion opponents rallied in Washington on Friday for the 50th annual "March for Life," marking a new chapter for a movement that has organized for decades around overturning Roe v. Wade, the landmark ruling that recognized a women's right to an abortion.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved
